Primære forskningsområder

Immuno-endocrinology and immuno-metabolism 

CV

CV (details on https://bmi.ku.dk/english/research-divisions/integrative-circulation/mandrup-poulsen-group/ )

Professor Mandrup-Poulsen is a physician scientist, board certified in internal medicine and endocrinology, who serves as Professor of Medical Research Methodology at the University of Copenhagen.

Education

• MD, University of Copenhagen (1980); DMSc, University of Copenhagen (1988)
  
  

Emploment

• 2007 - Professor in Medical Research Methodology, University of Copenhagen
  
  
• 2000 - 2006 and 2009 - Adjunct Professor in Immunodiabetology, Dept. of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
  
  
• 2009 -2011    Research chief physician, Hagedorn Research Institute
  
  
• 1995 -2008    Chief Physician, Steno Diabetes Center
  
  
• 1997-2000     Medical Director, Steno Diabetes Center
  
  

Scientific journals, societies, awards etc.

• Associate Editor and Advisory Board member of Diabetologia (1995-2001)
  
  
• Danish Society for Internal Medicine (Board Member), 1992-1997, President 1995-97
  
  
• Danish Study Group for Diabetes in Childhood, Member of Executive Board (1995-2001)
  
  
• Member of the executive board of the Scandinavian Society for the Study of Diabetes (1994-1998), President 1998
  
  
• Co-founder of the Øresund Diabetes Academy, 2003-2009, President 2007-2009
  
  
• Oskar Minkowski Award of the European Association of Diabetes (1994)
  
  
• Knud Lundbæk Award of the Scandinavian Society for the Study of Diabetes (2001)
  
  
• Member of the Executive Board, the Interleukin Foundation, USA (2010-)
  
  

Membership of major university committees, research councils, etc.

• Danish Diabetes Association, Medical Research Fund Council (1995–2002)
  
  
• JDRF Medical Science Review Board, NY, USA, (2001-2004, 2005-2008 and ad hoc member 2010-), 
  
  
• Mary Jane Kugel Award of the JDRF (2004); EASD Minkowski Prize Committee (2002-2004)
  
  
• Institut National de la Santé et de la Recherche Médicale (INSERM), Member of the Scientific Advisory Board (2004-2009)
  
  
• Programme National de Recherches sur le Diabete  en France (PNRD), grant reviewer (2003-2005)
  
  
• Member of the EASD Standardization Committee, Chairman (2005-2007)
  
  

Current research support

• Novo Nordisk Foundation.

Aktuel forskning

We work to prevent and cure type 1 and type 2 diabetes and its cardiovascular complications by investigating the circadian, inflammatory, metabolic, oxidative, and ageing-related pathogenic pathways, with the scope of identifying novel therapeutic targets to be tested in preclinical models and clinical trials.

Interesseområder

The Immuno-endocrinology lab employs an interdisciplinary and collaborative research strategy to unravel transcriptional, translational and posttranslational responses to stress by two complementary approaches: a hypothesis-driven approach evolving from new discoveries in the lab, and an unbiased screening approach employing systems biology and using functional genomics, transcriptomics, proteomics, secretomics and post-translatomics.

Our experimental tactics utilise systems biology, bioinformatics, and in silico modelling, cell-free and cell-based in vitro models, ex vivo and in vivo studies in induced and genetic experimental animals, as well as epidemiological analyses and biomarker studies.

Undervisnings- og vejledningsområder

Molecular biomedicine, endocrinology

Kort præsentation

Thomas Mandrup-Poulsen is a physician scientist, specialist in internal medicine and endocrinology. He is a pioneer in the field of immuno-metabolism with the discovery that inflammatory cytokines impair the function and viability of pancreatic islet b-cells (Diabetologia 1986, Science 1986), for which he was awarded the 1994 Minkowski Prize of the EASD. His research focuses on how to prevent and cure type 1 and type 2 diabetes and its cardiovascular complications by investigating the circadian, inflammatory, metabolic, and ageing-related pathogenic pathways, with the scope of identifying novel therapeutic targets to be tested in preclinical models and clinical trials.

His long-standing interest in the role of iron and oxidative stress in the causation of diabetes has led to numerous high-rank publications (Lancet 2001, Diab Care 2011, 2013, 2014, 2023, Cell Metabolism 2012, BMJ 2024, Nature Communications 2026)

He and colleagues conducted the first proof-of-concept clinical trial showing that pro-inflammatory cytokine antagonists improve glycemia and b-cell function in diabetic patients (NEJM 2007).

In recent year his group has focused on the mutual interplay between immune-metabolism and the circadian clock (iScience 2025, Science 2025)

His expertise covers basic molecular and cellular techniques in cell biology, stress signalling, genomics and proteomics, epigenetics, animal models, clinical intervention trials and pharmaco-genomic and biochemical biomarker studies.